[1] MAIMAITIJIANG A,HE D,LI D,et al. Progress in research of nanotherapeutics for overcoming multidrug resistance in cancer[J]. Int J Mol Sci,2024,25(18):9973.
[2] HAIDER T,PANDEY V,BANJARE N,et al. Drug resistance in cancer:mechanisms and tackling strategies[J]. Pharmacol Rep,2020,72(5):1125-1151.
[3] DENG X,SUN W,LI X,et al. An anti-CRISPR that represses its own transcription while blocking Cas9-target DNA binding[J]. Nat Commun,2024,15(1):1806.
[4] VAGHARI-TABARI M,HASSANPOUR P,SADEGHSOLTANI F,et al. CRISPR/Cas9 gene editing:a new approach for overcoming drug resistance in cancer[J]. Cell Mol Biol Lett,2022,27(1):49.
[5] TIAN Y,LEI Y,WANG Y,et al. Mechanism of multidrug resistance to chemotherapy mediated by P glycoprotein (review)[J]. Int J Oncol,2023,63(5):119.
[6] GUO N,LIU J B,LI W,et al. The power and the promise of CRISPR/ Cas9 genome editing for clinical application with gene therapy[J]. J Adv Res,2022,40:135-152.
[7] ZHANG H H,XIANG J,YIN B C,et al. Overcoming multidrug resistance by base-editing-induced codon mutation[J]. ACS Pharmacol Transl Sci,2023,6(5):812-819.
[8] KANBAR K,EL DARZI R,JAALOUK D E. Precision oncology revolution:CRISPR-Cas9 and PROTAC technologies unleashed[J]. Front Genet,2024,15:1434002.
[9] SHARMA A K,GIRI A K. Engineering CRISPR/Cas9 therapeutics for cancer precision medicine[J]. Front Genet,2024,15:1309175.
[10] XU Y,ZHU M. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer[J]. Clin Transl Oncol,2020,22(7):1105-1116.
[11] XIAO L,PENG Z,ZHU A,et al. Inhibition of RUNX1 promotes cisplatin-induced apoptosis in ovarian cancer cells[J]. Biochem Pharmacol,2020,180:114116.
[12] NGO H,LE H,SURH Y J. Nrf2,A target for precision oncology in cancer prognosis and treatment[J]. J Cancer Prev,2023,28(4):131-142.
[13] LIN S C,WU H L,YEH L Y,et al. Activation of the miR-371/372/373 miRNA cluster enhances oncogenicity and drug resistance in oral carcinoma cells[J]. Int J Mol Sci,2020,21(24):9442.
[14] LI T,LI S,KANG Y,et al. Harnessing the evolving CRISPR/Cas9 for precision oncology[J]. J Transl Med,2024,22(1):749.
[15] KR?譫L S K,KACZMARCZYK A,WOJNICKI K,et al. Aberrantly expressed RECQL4 helicase supports proliferation and drug resistance of human glioma cells and glioma stem cells[J]. Cancers(Basel),2020,12(10):2919.
[16] LIU B,DIAZ ARGUELLO O A,CHEN D,et al. CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation[J]. PLoS One,2020,15(5):e0232985.
[17] SAGAR S,LEIPHRAKPAM P D,THOMAS D,et al. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans[J]. Cancer Lett,2021,503:91-102.
[18] HUSSEN B M,RASUL M F,ABDULLAH S R,et al. Targeting miRNA by CRISPR/Cas in cancer:advantages and challenges[J]. Mil Med Res,2023,10(1):32.
[19] BALASUBRAMANIAN A,VELUSWAMI K,RAO S,et al. Exploring clustered regularly interspaced short palindromic repeats-crispr-associated protein 9 (CRISPR-Cas9) as a therapeutic modality for cancer:a scoping review[J]. Cureus,2024,16(7):e64324.
[20] ZHANG J,ZENG X,GUO Q,et al. Small cell lung cancer:emerging subtypes,signaling pathways,and therapeutic vulnerabilities[J]. Exp Hematol Oncol,2024,13(1):78.
[21] LEI P,JU Y,PENG F,et al. Applications and advancements of CRISPR-Cas in the treatment of lung cancer[J]. Front Cell Dev Biol,2023,11:1295084.
[22] FARNSWORTH D A,CHEN Y T,DE RAPPARD YUSWACK G,et al. Emerging molecular dependencies of mutant EGFR-driven non-small cell lung cancer[J]. Cells,2021,10(12):3553.
[23] XUE Z,DEMPLE B. Knockout and inhibition of Ape1:roles of ape1 in base excision DNA repair and modulation of gene expression[J]. Antioxidants (Basel),2022,11(9):1817.
[24] WANG H,TANG Z,LI T,et al. CRISPR/Cas9-Mediated gene knockout of ARID1A promotes primary progesterone resistance by downregulating progesterone receptor B in endometrial cancer cells[J]. Oncol Res,2019,27(9):1051-1060.
[25] ALLEMAILEM K S,ALMATROODI S A,ALMATROUDI A,et al. Recent advances in genome-editing technology with CRISPR/Cas9 variants and stimuli-responsive targeting approaches within tumor cells:a future perspective of cancer management[J]. Int J Mol Sci,2023,24(8):7052.
[26] BARGHOUT S H,AMAN A,NOURI K,et al. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity[J]. JCI Insight,2021,6(5):e141518.
[27] JUNG H R,OH Y,NA D,et al. CRISPR screens identify a novel combination treatment targeting BCL-X(L) and WNT signaling for KRAS/BRAF-mutated colorectal cancers[J]. Oncogene,2021,40(18):3287-3302.
[28] RUSHWORTH L K,HARLE V,REPISCAK P,et al. In vivo CRISPR/ Cas9 knockout screen:TCEAL1 silencing enhances docetaxel efficacy in prostate cancer[J]. Life Sci Alliance,2020,3(12):e2020-00770.
[29] MAKHOV P,SOHN J A,SEREBRIISKII I G,et al. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma[J]. Br J Cancer,2020,123(12):1749-1756.
[30] ARDELT M A,FR?魻HLICH T,MARTINI E,et al. Inhibition of cyclin-dependent kinase 5:a strategy to improve sorafenib response in hepatocellular carcinoma therapy[J]. Hepatology,2019,69(1):376-393.
[31] XU S,ZHAN M,JIANG C,et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer[J]. Nat Commun,2019,10(1):5492.
[32] ROCHA C,REILY ROCHA A,MOLINA SILVA M,et al. Revealing temozolomide resistance mechanisms via genome-wide CRISPR libraries[J]. Cells,2020,9(12):2573.
[33] TAO R,HAN X,BAI X,et al. Revolutionizing cancer treatment:enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology[J]. Front Immunol,2024,15:1354825.
[34] YANG Z,ZHANG Z,LI J,et al. CRISPRlnc:a machine learning method for lncRNA-specific single-guide RNA design of CRISPR/Cas9 system[J]. Brief Bioinform,2024,25(2):bbae066.
[35] ZHANG M L,LI H B,JIN Y. Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy[J]. Front Genet,2024,15:1364742.
[36] HAN H A,PANG J,SOH B S. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing[J]. J Mol Med (Berl),2020,98(5):615-632.
[37] UDDIN F,RUDIN C M,SEN T. CRISPR gene therapy:applications,limitations,and implications for the future[J]. Front Oncol,2020,10:1387.